RnRMarketResearch.com adds ?Premature Ejaculation - Pipeline Review, H1 2015? to its store. The report provides an overview of the Premature Ejaculation?s therapeutic pipeline.

(PRWeb May 27, 2015)

Read the full story at

New prescription pills called smart drugs are taken by England's college students. Prescription drug abuse is a growing epidemic in the United States as well and those with a dependency should seek immediate professional help found at a detox center such as Harbor Village.

(PRWeb August 25, 2013)

Read the full story at

GIA announces the release of a global report on Narcolepsy Therapeutics market. The global market for Narcolepsy Therapeutics is projected to exceed US$395 million by the year 2015. Though a relatively small market, the global narcolepsy market exhibited significant growth since 2003, driven by an increase in awareness about the disorder and substantial market penetration of two key drugs used in the treatment of narcolepsy - Provigil (Modafinil) and Xyrem (Sodium oxybate). Patent expiry of Provigil in 2012 and black box warning for Xyrem provide significant room for other novel therapeutics, especially those with enhanced safety and efficacy.

(PRWeb July 12, 2010)

Read the full story at

PROFIDERALL Becomes the First and Only 'Cognitive Energy Enhancer' Available Without a Prescription

(PRWeb October 27, 2009)

Read the full story at

Offered as a series of three live question and answer sessions premiering Tuesday, September 29, 2009, from 12:00 p.m.-1:00 p.m. ET, the continuing education series will translate new evidence in literature into improved treatment of sleep-wake disorders. Clinicians can earn up to 3.0 CE credits by completing all 3 parts; participation is available online or by phone.

(PRWeb September 10, 2009)

Read the full story at

The use of "brain enhancing" drugs is increasing at an alarming rate yet a superior, simpler, natural solution exists: a treadmill desk.

(PRWeb December 08, 2008)

Read the full story at

Cephalon, Inc. (Nasdaq:CEPH) today announced that the U.S. Food and Drug Administration (FDA) has approved TREANDA(R) (bendamustine hydrochloride) for Injection for the treatment of patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow disease. The American Cancer Society estimates that more than 15,000 new cases of this rare disease will be diagnosed in the United States this year. The TREANDA application as a CLL treatment received priority review from the FDA and was approved within six months of the September 2007 submission. Cephalon anticipates that TREANDA will be available to physicians and patients as a CLL treatment in the United States in April 2008.

(PRWeb March 20, 2008)

Read the full story at

Theories about what causes attention deficit hyperactivity disorder, or ADHD, are many and varied, with experts speculating on a wide range of probable causes ? genetics, environmental pollutants, food allergies and challenging home environments.

(PRWeb June 06, 2006)

Read the full story at

Brandon Erickson can forget about the good old days when you could play a video game for 70 hours straight and just snap a photograph of your high score and receive instant recognition as the new world record holder. Nowadays, you have to take a blood test and record the entire accomplishment on videotape.

(PRWeb May 19, 2005)

Read the full story at